Tell me about the bmy stock fda date coming up

The upcoming FDA date for Bristol-Myers Squibb (BMY) involves several key events, as summarized below:

1. Accelerated Approval Pathway: Bristol-Myers Squibb has multiple drugs in the accelerated approval pathway, including KRAZATI (Adagrasib) + Cetuximab for colorectal cancer and solid tumors, Augtyro (Repotrectinib) for solid tumors and cancer, and Breyanzi (lisocabtagene maraleucel) for mantle cell lymphoma, non-Hodgkin lymphoma, follicular lymphoma, and chronic lymphocytic leukemia.
2. FDA Approval Status: The FDA approval status for these drugs is pending, with some already approved, such as Abecma for melanoma. The pending approvals are expected to occur on June 21, 2024, for KRAZATI + Cetuximab, on June 15, 2024, for Augtyro, and on May 31, 2024, for Breyanzi in mantle cell lymphoma.
3. FDA Review Date: The FDA review dates are specific to each drug, with the most recent review being on April 5, 2024, for Abecma. The upcoming review dates are June 21, 2024, for KRAZATI + Cetuximab, June 15, 2024, for Augtyro, and May 31, 2024, for Breyanzi in mantle cell lymphoma.
4. FDA Review Round: All the drugs are in the first round of FDA review.
5. Indication: The drugs are being reviewed for various cancer indications, including colorectal cancer, solid tumors, non-Hodgkin lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and melanoma.

In conclusion, Bristol-Myers Squibb is anticipating a series of FDA approval events in the near future, with multiple drugs in the accelerated approval pathway, and review dates ranging from May 31 to June 21, 2024. These events are significant for the company as they can lead to new product launches and revenue growth opportunities, assuming the FDA reviews are successful and the drugs are found to be safe and effective for their intended uses.